Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors

Publisher： Bentham Science Publishers

E-ISSN： 1875-5607|13|4|530-540

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.13, Iss.4, 2013-04, pp. : 530-540

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel targets for VEGF-independent anti-angiogenic drugs

By Petrillo Marco   Scambia Giovanni   Ferrandina Gabriella  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 4, 2012-04 ,pp. : 451-472

Informa Healthcare

Access to resources Recommend Favorite

VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future

By  

Current Cancer Drug Targets, Vol. 11, Iss. 5, 2011-01 ,pp. : 624-653

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives

By  

Current Clinical Pharmacology, Vol. 5, Iss. 3, 2010-08 ,pp. : 166-177

Bentham Science Publishers

Access to resources Recommend Favorite

Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 10, Iss. 6, 2011-12 ,pp. : 497-508

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics of Anti‐VEGF Agent Aflibercept in Cancer Predicted by Data‐Driven, Molecular‐Detailed Model

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 11, 2015-11 ,pp. : 641-649

John Wiley & Sons Inc

Access to resources Recommend Favorite